|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols显示文摘Hepatocellular carcinoma(HCC) is one of the major malignant diseases in many healthcare systems. The growing number of new cases diagnosed each year is nearly equal to the number of deaths from this cancer. Worldwide, HCC is a leading cause of cancerrelated deaths, as it is the fifth most common cancer and the third most important cause of cancer related death in men. Among various risk factors the two are prevailing: viral hepatitis, namely chronic hepatitis C virus is a well-established risk factor contributing to the rising incidence of HCC. The epidemic of obesity and the metabolic syndrome, not only in the United States but also in Asia, tend to become the leading cause of the long-term rise in the HCC incidence. Today, the diagnosis of HCC is established within the national surveillance programs in developed countries while the diagnosis of symptomatic, advanced stage disease still remains the characteristic of underdeveloped countries. Although many different staging systems have been developed and evaluated the BarcelonaClinic Liver Cancer staging system has emerged as the most useful to guide HCC treatment. Treatment allocation should be decided by a multidisciplinary board involving hepatologists, pathologists, radiologists, liver surgeons and oncologists guided by personalized-based medicine. This approach is important not only to balance between different oncologic treatments strategies but also due to the complexity of the disease(chronic liver disease and the cancer) and due to the large number of potentially efficient therapies. Careful patient selection and a tailored treatment modality for every patient, either potentially curative(surgical treatment and tumor ablation) or palliative(transarterial therapy, radioembolization and medical treatment, i.e., sorafenib) is mandatory to achieve the best treatment outcome. | Danijel Galun Dragan Basaric Marinko Zuvela Predrag Bulajic Aleksandar Bogdanovic Nemanja Bidzic Miroslav Milicevic | 2015 | World Journal of Hepatology2015，7，20： | 13 |
| 2 | Clinical outcome in patients with hilar malignant strictures type Ⅱ Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage显示文摘BACKGROUND:Stenting of malignant hilar strictures remains a standard endoscopic treatment in patients with unresectable tumors.The aim of this two-center prospective study was to compare unilateral versus bilateral drainage in hilar malignant stenosis Bismuth-Corlette type II.METHODS:During a 3-year period,a total of 49 patients with hilar tumors(Bismuth-Corlette type II) were referred for endoscopic treatment,following the criteria of unresectability.Ultrasound,computed tomography scan and magnetic resonance cholangiopancreatography(MRCP) were previously performed in all patients in order to facilitate endoscopic retrograde cholangiopancreatography(ERCP).The stricture was first passed by the hydrophilic guide-wire and then contrast medium was injected.Mechanical bile duct dilation was performed,followed by plastic stent placement only in the liver lobe which was previously opacified.The procedures were performed under conscious sedation.The patients were followed up for the next 12 months with a stent exchange every 3 months.Primary outcome was assessed by patient survival in the first 12 months after the procedure.RESULTS:All 49 patients were treated with ERCP while 39(79.59%) had successful stent placement.Among these,32 had hilar cholangiocarcinoma(82%) and 7(18%) had gallbladder cancer.Two groups of patients had Bismuth II strictures:A,21 patients(54%) with unilateral contrast injection and drainage,and B,18(46%) with bilateral contrast injection and drainage.A total of 57 plastic stents were used(10 Fr,89%;11.5 Fr,11%).Group B showed a lower bilirubin level 7 days after the procedure(P=0.008).Early complications were cholangitis(3 patients,2 in group A and 1 in group B) and acute pancreatitis(2 patients,1 each in A and B) with no statistical difference between the groups.Late complications were stent migration(5 patients,1 in A and 4 in B) and stent clogging(6 patients,2 in A and 4 in B) showing a significant difference between the groups(P<0.01).The first stent replacement after 3 months was successful in 87% of patients(four died due to disease progression and one due to cardiopulmonary insufficiency) showing no statistical difference between the groups.At 6 months follow-up,72% patients survived,with no statistical difference between the groups.A final follow-up(12 months) showed the survival rate of 18%(4 patients from group A and 3 from group B)(P>0.05).CONCLUSIONS:A minimally invasive approach,based on the criterion that every bile duct being opacified needs to be drained,is associated with a lower incidence of early complications.Considering that the clinical outcome measured by bilirubin level was lower in patients with bilateral drainage 7 days after the procedure,we assumed that drainage of 50% or more of the liver volume leads to sufficient drainage effectiveness. | Milutin Bulajic Nikola Panic Miodrag Radunovic Radisav Scepanovic Radoslav Perunovic Predrag Stevanovic Tatjana Ille Maurizio Zilli Mirko Bulajic | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，2： | 8 |
| 3 | Modalities of testing Helicobacter pylori in patients with nonmalignant bile duct diseases显示文摘AIM: This paper describes the procedure of detection ofHelicobacter pylori ( H. pylori) in bile specimens in patientssuffering from benign diseases of biliary ducts (lithiasiswith/without nonspecific cholangitis).METHODS: The group of 72 patients entering the studyconsisted of 32 male and 40 female (45 % and 55 %,respectively). Bile was obtained during ERCP in 68 patients,and during cholecystectomy in 4 patients. A fast urease test(FUT) to determine the existence of H. pylori in gastricmucosa was carried out for all the patients during theendoscopic examination. The existence of genetic materialof H. pylori was determined by detection of ure A gene bythe method of nested PCR. The results of this reaction wereshown by electrophoresis on l0 g@ L-1 agarose gel in a bandof 256 bp.RESULTS: The majority of the patients included in our studyhad biliary lithiasis without signs of cholangitis (48 patients,67 %), whereas other patients were complicated bycholangitis (17 patients, 24 %). Seven patients (9 %) hadnormal ERCP, forming thus the control group. In the groupof patients with lithiasis 26 patients (54.2 %) had positivePCR of H. pylori in bile and among the patients withassociated cholangitis positive PCR was detected in 9patients (52.9 % ). Among the seven patients with nornalERCP only one (14 %) had positive PCR of H. pylori. Ahigh percentage of H. pylori infection of gastric mucosawas observed (57 patients, 79 % ) : It was also observed thatits slightly higher positivity was in the patients with distinctbile pathology: 81% FUT positive patients in the group withcholedocholithiasis alone and 76 % in the group withcholedocholithiasis associated with cholangitis. Seventy-onepercent of the patients with regular findings had positive FUT.CONCLUSION: The prevalence of H. pylori infection both inbile and in gastric mucosa in patients with benign diseasesof biliary ducts does not show a statistically significantdifference in relation to the prevalence of the same with thepatients with normal ERCP. The existence of H. pyloriinfection possibly does not play a role in pathogenesis ofbenign biliary diseases. | Milutin Bulajic Bojan Stimec Miroslav Milicevic Matthias Loehr Petra Mueller Ivan Boricic Nada Kovacevic Mirko Bulajic | 2002 | World Journal of Gastroenterology2002，8，2： | 6 |
| 4 | Helicobacter pylori and pancreatic diseases显示文摘A possible role for Helicobacter pylori(H. pylori) infec-tion in pancreatic diseases remains controversial. H. pylori infection with antral predomination leading to an increase in pancreatic bicarbonate output and induc-ing ductal epithelial cell proliferation could contribute to the development of pancreatic cancer via complex interactions with the ABO genotype, dietary and smok-ing habits and N-nitrosamine exposure of the host. Although the individual study data available so far is inconsistent, several meta-analyses have reported an increased risk for pancreatic cancer among H. pylori seropositive individuals. It has been suggested that H. pylori causes autoimmune pancreatitis due to molecu-lar mimicry between H. pylori a-carbonic anhydrase(a-CA) and human CA type Ⅱ, and between H. pylori plasminogen-binding protein and human ubiquitin-protein ligase E3 component n-recognin 2, enzymes that are highly expressed in the pancreatic ductal andacinar cells, respectively. Future studies involving large numbers of cases are needed in order to examine the role of H. pylori in autoimmune pancreatitis more fully. Considering the worldwide pancreatic cancer burden, as well as the association between autoimmune pan-creatitis and other autoimmune conditions, a complete elucidation of the role played by H. pylori in the gen-esis of such conditions could have a substantial impact on healthcare. | Milutin Bulajic Nikola Panic Johannes Matthias Lohr | 2014 | World Journal of Gastrointestinal Pathophysiology2014，5，4： | 3 |
| 5 | 多支架治疗慢性重症胰腺炎中难治性胰管狭窄的远期疗效显示文摘Background and Study Aims:Dominant pancreatic duct strictures located in the head of the pancreas in patients with severe chronic pancreatitis are often managed by endoscopic placement of a single plastic stent.Patients with refractory strictures after prolonged stenting require repeated stent replacement or surgical pancreaticojejunostomy.Placement of multiple plastic stents has proved effective in managing postoperative biliary strictures.The aim of this study was to investigate the feasibility,efficacy,and long-term results of multiple stenting of refractory pancreatic strictures in severe chronic pancreatitis.Patients and Methods:19 patients with severe chronic pancreatitis(16 men,three women;mean age 45 years)and with a single pancreatic stent through a refractory dominant stricture in the pancreatic head underwent the following protocol:(i)removal of the single pancreatic stent;(ii)balloon dilation of the stricture;(iii)insertion of the maximum number of stents allowed by the stricture tightness and the pancreatic duct diameter;and(iv)removal of stents after 6 to 12 months.Results:The median number of stents placed through the major or minor papilla was 3,with diameters ranging from 8.5 to 11.5 Fr and length from 4 to 7 cm.Only one patient(5.5%)had persistent stricture after multiple stenting.During a mean follow-up of 38 months after removal,84%of patients were asymptomatic,and 10.5%had symptomatic stricture recurrence.No major complications were recorded.Conclusion:Endoscopic multiple stenting of dominant pancreatic duct strictures in chronic pancreatitis is a feasible and safe technique.Multiple pancreatic stenting is promising in obtaining persistent stricture dilation on long-term follow-up in the setting of severe chronic pancreatitis. | Costamagna G. Bulajic M. Tringali A. 孟欣颖 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，9： | 2 |
| 6 | Efficient oxidative folding of conotoxins and the radiation of venomous cone snails 显示文摘 | Bulaj G Buczek O Goodsell I el at | 2003 | Proe Nad Aead Sei USA2003，100，14： | 1 |
| 7 | μ-Conotoxin Sm Ⅲ A,a potent inhibitor of tetrodotoxin-resistant sodium channels in amphibian sympathetic and sensory neurons显示文摘 | West P J Bulaj G Garrett J E | 2002 | Biochemistry2002，41，15： | 1 |
| 8 | Novel conotoxins from conus striatus and conus kinoshitai selectively block TTX-resistant sodium channels显示文摘 | Bulaj G West P J Garrett J E | 2005 | Biochemistry2005，44，19： | 1 |
| 9 | Efficient oxidative folding of conotoxin sand the radiation of venomous cone snails显示文摘 | Bulaj G Buczek O Goodsell I | 2003 | Proceedings of the National Academy of Sciences USA2003，100，14： | 1 |
| 10 | Is There any Benefit from Expanding the Criteria for the Resection of Hepatocellular Carcinoma in Cirrhotic Liver? Experience from a Developing Country显示文摘 | Danijel Galun Predrag Bulajic Marinko Zuvela Dragan Basaric Tatjana Ille Miroslav Milicevic | 2012 | World Journal of Surgery2012，，7： | 1 |
| 11 | Multiple stent- ing of refractory pancreatic duct strictures in severe chronic pancreatitis: long term results显示文摘 | Costamagna G Bulajic M Tringali A | 2006 | Endoscopy2006，38，： | 1 |
| 12 | Multiple Stenting of Refractory Pancreatic Duct Strictures in Severe Chronic Pancreatitis: Long-term Results显示文摘 | G. Costamagna M. Bulajic A. Tringali M. Pandolfi A. Gabbrielli C. Spada L. Petruzziello P. Familiari M. Mutignani | 2006 | Endoscopy2006，，03： | 1 |
| 13 | Endoscopic removal of malfunctioning biliary self-expandable metallic stents显示文摘 | Familiari P Bulajic M Mutignani M | 2005 | Gastrointest Endosc2005，62，6： | 1 |
| 14 | WConotoxin SmIIIA, a potent inhibitor of TTX-resistant sodium channels in amphibian sympathetic and sensory neurons 显示文摘 | West PJ Bulaj G Garrett JE | 2002 | Biochemistry2002，41，15： | 1 |
| 15 | Folding of eonotoxins: formation of the native disulfide bridges during chemical synthesis and biosynthesis of conus peptides 显示文摘 | Bulaj G Olivera BM | 2008 | Antio Redox Sig2008，10，1： | 1 |
| 16 | Colorectal cancer screening in a low-incidence area: general invitation versus family risk targeting: a comparative study from Montenegro显示文摘 | Nikola Panic Thomas R?sch Brigita Smolovic Miodrag Radunovic Mirko Bulajic Aleksandra Pavlovic-Markovic Zoran Krivokapic Srdjan Djuranovic Tatjana Ille Milutin Bulajic | 2015 | European Journal of Gastroenterology & Hepatology2015，，10： | 1 |
| 17 | Conotoxins-new vistas for peptide therapeutics显示文摘 | Jones R M Bulaj G | 2000 | Curr Pharm Des2000，6，12： | 1 |
| 18 | Efficient oxidative folding of conotoxins and the radiation of venomous cone snails显示文摘 | Bulaj G Buczek O Goodsell I | 2003 | Proc Natl Acad Sci U S A2003，100，14： | 1 |
| 19 | First report of Alternaria mali on apples in Yugaslavia 显示文摘 | BULAJIC A | 1996 | Plant Disease1996，80，6： | 1 |
| 20 | Total chemical synthesis and oxidative folding of delta-eonotoxin PVIA containing an Nterminal propeptide显示文摘 | Buezek P Buezek O Bulaj G | 2005 | Biopol3qners2005，80，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员